Clinical trials: Dengue
Dengue Fever, Dengue Hemorrhagic Fever
Immunogenicity and Safety of Different Vaccination Schedules of Tetravalent Dengue Vaccine in Healthy Subjects 9 to 50 Years of Age
The aim of the study was to assess the immune response and the safety of different vaccination schedules of CYD dengue vaccine. The primary objectives of the study were: To demonstrate the non-inferiority of the immune response…
- Trial name
- NCT02628444
- Testing
- CYD Dengue Vaccine
- Where
- 6 sites in Colombia, Philippines
- Volunteers
- 1,050 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Dengue Fever, Fever
Prospective Surveillance of Febrile Illness for Dengue-Endemic Areas in Asia
The purpose of this study is to detect acute febrile episodes and dengue infection in five Asian countries, to assess dengue seroprevalence, and to assess surveillance infrastructure at investigational sites in anticipation of a…
- Trial name
- NCT01218906
- Where
- 11 sites in Indonesia, Malaysia and 3 more
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- Sanofi
Dengue Shock Syndrome, Dengue Hemorrhagic Fever
Safety of and Immune Response to DEN4 Vaccine Component Candidate for Dengue Virus
Infection with dengue viruses is one of the leading causes of hospitalization and death in children in several tropical Asian counties.
- Trial name
- NCT00919178
- Testing
- DEN4 Vaccine Candidate
- Where
- 2 sites in United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Dengue
Expansion of a Dengue-1 Live Virus Human Challenge
To evaluate the effectiveness of candidate dengue vaccine formulations, it is prudent to develop an appropriate challenge model.
- Trial name
- NCT03869060
- Testing
- Dengue-1 Virus-Live Virus Human Challenge (DENV-1-LVHC)
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- State University of New York - Upstate Medical University
DENV Without Warning Signs, DENV with Warning Signs
Innovative Multidisciplinary Strategies for Combating Severe Dengue
The goal of this observational study is to identify biomarkers and host factors associated with dengue severity in patients from dengue-endemic regions.
- Conditions
- DENV Without Warning Signs, DENV with Warning Signs, Severe Dengue, Healthy Controls Group - Age and Sex-matched
- Trial name
- COMBAT (NCT06751836)
- Testing
- Infection and no infection
- Where
- 2 sites in Guatemala, India
- Volunteers
- 1,400 people, healthy volunteers welcome
- Sponsor
- Karolinska Institutet
Dengue, Dengue Hemorrhagic Fever
Study of CYD Dengue Vaccine in Healthy Children and Adolescents in South America
The purpose of this study is to generate immunogenicity and safety data in preparation for efficacy studies in Latin America. Primary Objectives: To describe the immune response to dengue viruses before and after each vaccination…
- Trial name
- NCT01187433
- Testing
- Live, attenuated, recombinant dengue serotype 1 , 2, 3 , and 4 virus, NaCl 0.9%, Tetanus toxoid, reduced diphtheria toxoid, acellular pertussis vaccine adsorbed
- Where
- Brazil
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Dengue Vaccines
Characterisation of Dengue Vaccine-induced Specific Immunity in Vaccinees With and Without Prior Exposure to Flavivirus Infections or Vaccination
The goal of this observational study is to learn about the immunity induced by the Qdenga® vaccine in vaccinees. Participants that will receive the Dengue vaccine as part of their routine before a travel will be asked to undergo…
- Trial name
- VaQDENV (NCT06776692)
- Testing
- Qdenga
- Where
- Italy
- Volunteers
- 402 people, healthy volunteers welcome
- Sponsor
- IRCCS Sacro Cuore Don Calabria di Negrar
Dengue Hemorrhagic Fever, Awareness
Evaluating Public Awareness and Preventive Actions for Dengue Fever in Sudan Amidst Ongoing Crises
This study evaluates the awareness of dengue fever and preventive measures among Sudanese people during the war. It assesses knowledge, awareness, implementation of prevention, access to healthcare, community involvement, and the…
- Trial name
- NCT07205848
- Testing
- No intervention
- Where
- Sudan
- Volunteers
- 164 people, healthy volunteers welcome
- Sponsor
- Research and Publication office
Dengue Fever
Lot-to-lot Consistency of 3 Lots of Tetravalent Dengue Vaccine (TDV) in Non-endemic Country(Ies) for Dengue
The purpose of this study is to investigate lot-to-lot consistency in terms of equivalence of the immune responses induced by 3 consecutive TDV lots in healthy participants aged 18 to 60 years in non-endemic country(ies) for…
- Trial name
- NCT03423173
- Testing
- TAK-003
- Where
- 14 sites in United States
- Volunteers
- 923 people, healthy volunteers welcome
- Sponsor
- Takeda
Dengue Fever
Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3delta30/31-7164) in Healthy Adults
Dengue fever, which is caused by dengue viruses, is a major health problem in tropical and subtropical regions of the world. The purpose of this study is to test the safety of and immune response to a new dengue virus vaccine in…
- Trial name
- NCT00831012
- Testing
- rDEN3delta30/31-7164
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Dengue, Dengue Vaccines
This Study Will Describe the Burden of DENgue Fever Virus (DENV) Illness Among Household Members Aged 6 Months to 50 Years of Selected Communities in Latin America and Southeast Asia
The purpose of this study is to describe the burden of DENV illness among household members aged 6 months to 50 years of selected communities in Latin America and Southeast Asia.
- Trial name
- NCT02766088
- Testing
- Blood sample collection
- Where
- 2 sites in Mexico, Philippines
- Volunteers
- 1,750 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Dengue
Serological Study of Dengue and Characterization of Immune Response in Ten Endemic and Non-Endemic Cities in Mexico
Background: Dengue continues to be a high priority disease for public health in tropical and subtropical countries, where vector control measures have not had the expected impact on transmission.
- Trial name
- NCT04947111
- Testing
- Estimate the distribution of antibodies by serotype by Dengue virus in areas of low and high incidence of dengue
- Where
- Mexico
- Volunteers
- 1,960 people, healthy volunteers welcome
- Sponsor
- Mexican Society of Public Health
Dengue
Prospective Study of Infant Dengue
Dengue is a common disease and a major health concern in the Philippines. Dengue is caused by a virus transmitted from the bite of an infected mosquito.
- Trial name
- NCT00377754
- Where
- Philippines
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
West Nile Fever Encephalitis
Safety of and Immune Response to a West Nile Virus Vaccine (WN/DEN4-3'delta30) in Healthy Adults
West Nile (WN) virus infection is an emerging disease; WN infection may lead to paralysis, coma, and death. The purpose of this study is to test the safety of and immune response to a WN vaccine in healthy adults.
- Trial name
- NCT00094718
- Testing
- WN/DEN4-3'delta30
- Where
- 2 sites in United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Dengue, Vector Borne Diseases
Sustainable Reduction of Dengue in Colombia: Vector Breeding Site Intervention With an Insecticidal Coating
Effective control of Aedes aegypti mosquitoes in breeding sites with high reproductive rates could have a major impact on reducing arbovirosis in endemic communities.
- Conditions
- Dengue, Vector Borne Diseases, Arbovirus Infections, Zika
- Trial name
- NCT06268691
- Testing
- Insecticide Coating INESFLY
- Where
- 2 sites in Colombia, Germany
- Volunteers
- 35,000 people, healthy volunteers welcome
- Sponsor
- Rocio Cardenas Sanchez
Dengue Fever
A Study to Monitor the Adverse Events of QDENGA Vaccine in Participants in Malaysia
The main aim of this study is to collect the number and type of medical problems (adverse events) after vaccination with QDENGA in Malaysia and to learn more about such medical problems after vaccination.
- Trial name
- PRIME-Q (NCT06388785)
- Testing
- No Intervention
- Where
- 2 sites in Malaysia
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Takeda
Dengue
Follow-up the Health Condition , Investigation of the Immuno-regulation , and the Study for Interaction of Viral Hepatitis--- Among Patients With or After Dengue Fever Infection
Originally test host's to understand the tracking healthily and immune change of the dengue fever in Taiwan. Blood drawing 20 c.c for liver examination, kidney and other biochemical function, analyze host immunity adjusts and…
- Trial name
- NCT00629356
- Testing
- dengue fever
- Where
- Taiwan
- Volunteers
- healthy volunteers welcome
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Dengue
Phase II Trial to Evaluate Safety and Immunogenicity of a Dengue 1,2,3,4 (Attenuated) Vaccine
This is a phase II step-wise, randomized, multicenter, double-blind and controlled clinical trial to evaluate the safety and immunogenicity of a attenuated tetravalent lyophilized dengue vaccine manufactured by Butantan…
- Trial name
- NCT01696422
- Testing
- Dengue 1,2,3,4 (attenuated) vaccine, TetraVax-DV Vaccine - Admixture TV003
- Where
- 2 sites in Brazil
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Butantan Institute
Healthy
Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric Dengue Vaccine in Healthy Volunteers Between the Ages of 1.5 - 45 Years
The purpose of this study is to assess the safety of Takeda's tetravalent dengue vaccine (TDV) (previously DENVax) administered subcutaneously in healthy adults and children.
- Trial name
- NCT01511250
- Testing
- TDV
- Where
- 8 sites in Colombia, Puerto Rico and 2 more
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Takeda
Dengue
Safety and Immunogenicity of the Dengue Virus Vaccine TV005 (TetraVax-DV TV005) in Healthy Adults, Adolescents, and Children in Dhaka, Bangladesh
The purpose of this study is to evaluate the safety and immunogenicity of the recombinant live attenuated tetravalent dengue virus vaccine admixture TV005 (TetraVax-DV T005) in healthy adults, adolescents, and children in Dhaka…
- Trial name
- NCT02678455
- Testing
- TV005 vaccine
- Where
- Bangladesh
- Volunteers
- 192 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)